Vertex's cystic fibrosis drugs are among the most expensive ever evaluated by the US Institute for Clinical and Economic Research.
Could pricing pressure lead to the end of incremental innovation – and why does this matter?
Consolidation of hospital chains could give biopharma another powerful group of payers to contend with.
Amid a backlash over the high prices of advanced therapies, biotech companies are coming up with new payment models.
How the EMA's move out of London could impact European drug approvals.
Next-generation projects, including gene therapies, could soon be shaking up the haemophilia market.
Experts expect Roche's Hemlibra to dominate the inhibitor patient population, but to be a big deal it will need to impress in non-inhibitor patients, too.